https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 The contribution of respiratory microbiome analysis to a treatable traits model of care https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48068 Wed 22 Feb 2023 16:37:56 AEDT ]]> Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34787 Wed 19 Jan 2022 15:18:05 AEDT ]]> Soluble fibre supplementation with and without a probiotic in adults with asthma: a 7-day randomised, double blind, three way cross-over trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45086 25 billion CFU) and placebo. Plasma SCFA, sputum cell counts and inflammatory gene expression, asthma control gut microbiota, adverse events including gastrointestinal symptoms were measured. Findings: There was no difference in change in total plasma SCFA levels (μmol/L) in the placebo versus soluble fibre (Δmedian [95% CI] 16·3 [−16·9, 49·5], p = 0·335) or soluble fibre+probiotic (18·7 [−14·5, 51·9], p = 0·325) group. Following the soluble fibre intervention there was an improvement in the asthma control questionnaire (ACQ6) (∆median (IQR) -0·35 (−0·5, −0·13), p = 0·006), sputum %eosinophils decreased (−1.0 (−2·5, 0), p = 0·006) and sputum histone deacetylase 9 (HDAC9) gene expression decreased (−0.49 (−0.83, −0.27) 2-ΔCt, p = .008). Individual bacterial operational taxonomic units changed following both inulin and inulin+probiotic arms. Interpretation: Soluble fibre supplementation for 7 days in adults with asthma did not change SCFA levels. Within group analysis showed improvements in airway inflammation, asthma control and gut microbiome composition following inulin supplementation and these changes warrant further investigation, in order to evaluate the potential of soluble fibre as a non-pharmacological addition to asthma management.]]> Thu 27 Oct 2022 14:06:45 AEDT ]]> The influence of early-life microbial exposures on long-term respiratory health https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53400 Thu 23 Nov 2023 13:43:38 AEDT ]]> Neutrophils in asthma: The good, the bad and the bacteria https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53382 Thu 23 Nov 2023 12:54:42 AEDT ]]> Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53381 Thu 23 Nov 2023 12:19:50 AEDT ]]> Long-Term Azithromycin reduces haemophilus influenzae and increases antibiotic resistance in severe asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47850 Thu 02 Feb 2023 16:46:49 AEDT ]]> The effects of increasing fruit and vegetable intake in children with asthma: A randomized controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39780 Mon 25 Jul 2022 11:26:17 AEST ]]> Therapeutic Targeting of the Respiratory Microbiome https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51767 Mon 18 Sep 2023 14:30:18 AEST ]]> Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33089 Fri 24 Aug 2018 16:46:54 AEST ]]> Rothia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47445 Fri 20 Jan 2023 14:08:31 AEDT ]]>